ÌÇÐÄvlog´«Ã½

Endobronchial Ultrasound Biopsy Market Analysis

The Endobronchial Ultrasound Biopsy Market is expected to register a CAGR of 4.36% during the forecast period.

Respiratory disorders such as chronic obstructive pulmonary disorder (COPD), tuberculosis, and lung and bronchus cancer use endobronchial ultrasound biopsy to obtain tissue or fluid samples from the lungs and surrounding lymph nodes without conventional surgery to diagnose and detect the severity of diseases. For instance, according to 2024 statistics published by the American Lung Association, an estimated 11.7 million, or 4.6% of the adult population, in the United States were given a COPD diagnosis in 2022. This translates to a large patient pool potentially requiring diagnosis. Similarly, according to the Australian Bureau of Statistics 2022 update, adults aged 65 years and above are significantly more likely to have COPD, with roughly one in fourteen (7.0%) being diagnosed. Therefore, the rising prevalence of respiratory disorders is a potential driver for the endobronchial ultrasound biopsy market.

Additionally, while smoking is the leading cause of COPD, particularly in high-income countries, household air pollution is another significant risk factor in low- and middle-income countries (LMICs). This is especially concerning as smoking rates are on the rise in LMICs, suggesting a potential explosion of COPD cases in the coming decades. As the global COPD burden grows, particularly in LMICs, the demand for accurate and early diagnosis tools like EBUS is expected to rise in the near future. This overall growth in respiratory illnesses is likely to drive up the demand for accurate and minimally invasive diagnostic tools like EBUS during the forecast period.

Furthermore, according to the World Health Organization Report 2023, an estimated global total of 10.6 million people (ranging from 9.9 to 11.4 million) contracted TB, translating to 133 incident cases per 100,000 individuals. The majority of TB cases in 2022 were concentrated in the WHO regions of Southeast Asia (46%), Africa (23%), and the Western Pacific (18%), with smaller proportions in the Eastern Mediterranean (8.1%), the Americas (3.1%), and Europe (2.2%) in 2022. While TB primarily affects the lungs, it can also spread to other parts of the body (extrapulmonary TB). EBUS can be a valuable tool in diagnosing extrapulmonary TB cases by guiding needle biopsies of lymph nodes or other affected tissues. The number of tuberculosis (TB) cases is expected to rise, further fueling the demand for endobronchial ultrasound biopsy for this specific region.

Therefore, owing to the aforementioned factors, such as the high burden of respiratory diseases and increasing demand for minimally invasive procedures, the market is anticipated to witness growth during the forecast period. However, the high cost of equipment and lack of reimbursement policies in developing countries are likely to restrain the market's growth.

Endobronchial Ultrasound Biopsy Industry Segmentation

As per the scope of the report, endobronchial ultrasound is a technique for biopsy and visualization of the structure around the tracheobronchial tree.

The endobronchial ultrasound biopsy market is segmented by product, application, and geography. By product, the market is segmented into biopsy forceps, cytology brushes, biopsy needles, transbronchial aspiration needles, spray catheters, and other products. By application, the market is segmented into cancer diagnosis, infection diagnosis, and other applications. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the value (USD) for the above segments.